{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:42:04Z","timestamp":1781739724670,"version":"3.54.5"},"reference-count":30,"publisher":"PAGEPress Publications","issue":"3","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Objectives: The aim of this study was to investigate the impact of the addition of 50 mg daily sildena\ufb01l to pentoxifylline-colchicine combination ther-apy on the Peyronie's plaque features in patients with the acute phase of Peyronie's disease (PD). Methods: In this retrospective and non-randomized clinical study, patients were divided into 2 groups as group 1; (n = 107) who received colchicine and pentoxy\ufb01llin plus 50 mg daily oral sildena\ufb01l, and as group 2; (n = 79) who received only colchicine and pentoxy\ufb01llin. Patients were compared in terms of degree of curvature, pain in erection and erectile function at the baseline and at 6-month follow up. Pain in erection and erectile func-tion were evaluated by visual Analogue Scale (EF-VAS), and the shortened version of the International Index of Erectile Function (IIEF-5). Improvement in the degree of curvature and change in EF-VAS scores were primary endpoints of the study. Change in IIEF-5 score was the secondary endpoint of the study. Results: The two groups were statistically similar in terms of demographics and baseline features of PD. A statistically signi\ufb01-cant reduction in degree of curvature and EF-VAS scores was shown in group 1 compared to group 2.There was also a signi\ufb01-cantly higher IIEF-5 score in group 1 compared to group 2. No signi\ufb01cant side effects were detected in both groups during treatment period.Conclusions: Adding sildena\ufb01l to pentoxifylline-colchicine com-bination treatment seems to improve PD related symptoms in the acute phase PD. PDE5i may contribute to relieve the Peyronie's symptoms in ED patients through their anti\ufb01brotic effects.<\/jats:p>","DOI":"10.4081\/aiua.2022.3.319","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T14:32:50Z","timestamp":1664202770000},"page":"319-322","source":"Crossref","is-referenced-by-count":4,"title":["Effects of long term sildena\ufb01l on the acute phase of Peyronie\u2019s disease in a combination treatment"],"prefix":"10.4081","volume":"94","author":[{"given":"Murat","family":"Topcuoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"\u00c7akan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"59521","doi-asserted-by":"crossref","unstructured":"Tunuguntla. HS. Management of Peyronie's disease a review. World J Urol. 2001; 19:244-250.","DOI":"10.1007\/s003450100209"},{"key":"59522","doi-asserted-by":"crossref","unstructured":"Kadioglu A, Tefekli A, Erol B, et al. Retrospective review of 307 men with Peyronie\u2019s disease. J Urol. 2002; 168:1075.","DOI":"10.1016\/S0022-5347(05)64578-8"},{"key":"59523","doi-asserted-by":"crossref","unstructured":"Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001; 88:727-30.","DOI":"10.1046\/j.1464-4096.2001.02436.x"},{"key":"59524","doi-asserted-by":"crossref","unstructured":"Bilgutay AN, Pastuszak AW. Peyron\u0131e's disease: a review of etiol-ogy, diagnosis, and management. Curr Sex Health Rep. 2015; 7:117-131.","DOI":"10.1007\/s11930-015-0045-y"},{"key":"59525","doi-asserted-by":"crossref","unstructured":"Chung E, Ralph D, Kadioglu A, et al. Evidence-based management guidelines on Peyronie's disease. J Sex Med. 2016; 13:905-923.","DOI":"10.1016\/j.jsxm.2016.04.062"},{"key":"59526","doi-asserted-by":"crossref","unstructured":"Ferrini MG, Davila H, Kovanecz I, et al. Long-term continuous treatment with vardena\ufb01l prevents \ufb01brosis and preserves smooth muscle content in the rat corpora cavernosa after bilateral cavernos-al nerve transection. Urology. 2006; 68:429-435.","DOI":"10.1016\/j.urology.2006.05.011"},{"key":"59527","doi-asserted-by":"crossref","unstructured":"Ilg MM, Mateus M, Stebbeds WJ, et al. Anti-\ufb01brotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie\u2019s disease models. Eur Urol. 2019; 75:329-340.","DOI":"10.1016\/j.eururo.2018.10.014"},{"key":"59528","doi-asserted-by":"crossref","unstructured":"Kadiog\u02d8lu A, Tefekli A, Erol H, et al. Color Doppler ultrasound assessment of penile vascular system in men with Peyronie's disease. Int J Impot Res. 2000; 12:263-7","DOI":"10.1038\/sj.ijir.3900569"},{"key":"59529","doi-asserted-by":"crossref","unstructured":"Vande Berg JS, Devine CJ, Horton CE, et al. Mechanisms of calci-\ufb01cation in Peyronie's disease. J Urol. 1982; 127:52-54.","DOI":"10.1016\/S0022-5347(17)53599-5"},{"key":"59530","doi-asserted-by":"crossref","unstructured":"Ibrahim A, Gazzard L, Alharbi M, et al. Evaluation of oral pen-toxifylline, colchicine, and penile traction for the management of Peyronie\u2019s disease. Sex Med. 2019; 7:459-63.","DOI":"10.1016\/j.esxm.2019.07.003"},{"key":"59531","doi-asserted-by":"crossref","unstructured":"Hellstrom WJ, Bivalacqua TJ. Peyronie's disease: etiology, med-ical, and surgical therapy. J Androl 2000; 21:347-354.","DOI":"10.1002\/j.1939-4640.2000.tb03387.x"},{"key":"59532","doi-asserted-by":"crossref","unstructured":"Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU Guidelines on penile curvature. Eur Urol. 2012; 62:543-52.","DOI":"10.1016\/j.eururo.2012.05.040"},{"key":"59533","doi-asserted-by":"crossref","unstructured":"Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie\u2019s disease: AUA Guideline. J Urol. 2015; 194:745-753.","DOI":"10.1016\/j.juro.2015.05.098"},{"key":"59534","doi-asserted-by":"crossref","unstructured":"Chiao TB, Lee AJ. RoLe of pentoxifylline and vitamin E in atten-uation of radiation-induced \ufb01brosis. Ann Pharmacother. 2005; 39:516-522.","DOI":"10.1345\/aph.1E186"},{"key":"59535","doi-asserted-by":"crossref","unstructured":"Safarinejad MR, Asgari MA, Hosseini SY, Farid D. A double-blind placebo-controlled study of the ef\ufb01cacy and safety of pentoxifylline in early chronic Peyronie\u2019s disease. BJU Int. 2009; 106:240-248.","DOI":"10.1111\/j.1464-410X.2009.09041.x"},{"key":"59536","doi-asserted-by":"crossref","unstructured":"Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil ef\ufb01cacy in Peyronie's disease comparing with pentoxifylline. Glob J Health Sci. 2014; 6(7 Spec No):23-30.","DOI":"10.5539\/gjhs.v6n7p23"},{"key":"59537","doi-asserted-by":"crossref","unstructured":"Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol. 2006; 3:111-5.","DOI":"10.1038\/ncpuro0409"},{"key":"59538","doi-asserted-by":"crossref","unstructured":"Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int. 2003; 91:522-4.","DOI":"10.1046\/j.1464-410X.2003.04134.x"},{"key":"59539","doi-asserted-by":"crossref","unstructured":"Akkus E, Breza J, Carrier S, et al. Is colchicine effective in Peyronie\u2019s disease? A pilot study. Urology. 1994; 44:291-295.","DOI":"10.1016\/S0090-4295(94)80155-X"},{"key":"59540","doi-asserted-by":"crossref","unstructured":"Vernet D, Magee T, Qian A, et al. Phosphodiesterase type 5 is not upregulated by tadala\ufb01l in cultures of human penile cells. J Sex Med. 2006; 3:84-94.","DOI":"10.1111\/j.1743-6109.2005.00197.x"},{"key":"59541","doi-asserted-by":"crossref","unstructured":"El-Sakka AI, Hassoba HM, Pillarisetty RJ, et al. Peyronie\u2019s dis-ease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997; 158:1391-1394.","DOI":"10.1016\/S0022-5347(01)64223-X"},{"key":"59542","doi-asserted-by":"crossref","unstructured":"Dunkern TR, Feurstein D, Rossi GA, et al. Inhibition of TGF-b induced lung \ufb01broblast to myo\ufb01broblast conversion by phosphodi-esterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol. 2007; 572:12-22.","DOI":"10.1016\/j.ejphar.2007.06.036"},{"key":"59543","doi-asserted-by":"crossref","unstructured":"Wang-Rosenke Y, Neumayer HH, Peters H. NO signaling through cGMP in renal tissue \ufb01brosis and beyond: key pathway and novel therapeutic target. Curr Med Chem. 2008; 15:1396-1406.","DOI":"10.2174\/092986708784567725"},{"key":"59544","doi-asserted-by":"crossref","unstructured":"Valente EG, Vernet D, Ferrini MG, et al. L-arginine and phos-phodiesterase (PDE) inhibitors counteract \ufb01brosis in the Peyronie's \ufb01brotic plaque and related \ufb01broblast cultures. Nitric Oxide. 2003; 9:229-44.","DOI":"10.1016\/j.niox.2003.12.002"},{"key":"59545","doi-asserted-by":"crossref","unstructured":"Gholami SS, Gonzalez-Cadavid NF, Lin CS, et al. Peyronie\u2019s dis-ease: a review. J Urol. 2003; 169:1234.","DOI":"10.1097\/01.ju.0000053800.62741.fe"},{"key":"59546","doi-asserted-by":"crossref","unstructured":"Cakan M, Akman T, Oktar T, et al. The clinical characteristics of Peyronie's patients with notching deformity. J Sex Med. 2007; 4:1174-1178.","DOI":"10.1111\/j.1743-6109.2006.00258.x"},{"key":"59547","doi-asserted-by":"crossref","unstructured":"Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar modeling: assessment of clinical and radiological outcomes. J Sex Med. 2011; 8:1472-7.","DOI":"10.1111\/j.1743-6109.2011.02217.x"},{"key":"59548","doi-asserted-by":"crossref","unstructured":"Ozturk U, Yesil S, Goktug HN, et al. Effects of sildena\ufb01l treat-ment on patients with Peyronie's disease and erectile dysfunction. Ir J Med Sci. 2014; 183:449-53.","DOI":"10.1007\/s11845-013-1036-5"},{"key":"59549","doi-asserted-by":"crossref","unstructured":"Palmieri A, Imbimbo C, Creta M, et al. Tadala\ufb01l once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012; 35:190-195.","DOI":"10.1111\/j.1365-2605.2011.01226.x"},{"key":"59550","doi-asserted-by":"crossref","unstructured":"Levine LA, Green\ufb01eld JM. Establishing a standardized evaluation of the man with Peyronie\u2019s disease. Int J Impot Res. 2003; 15:S103-S112.","DOI":"10.1038\/sj.ijir.3901083"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/download\/aiua.2022.3.319\/10350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/download\/aiua.2022.3.319\/10350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T19:05:54Z","timestamp":1701111954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/view\/aiua.2022.3.319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9,26]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2022.3.319","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}